TransCode Therapeutics, Inc. RNAZ 深 沪
等待开盘 08-25 09:30:00 美东时间
2.70
-0.170
-5.92%
华盛通- 最 高2.91
- 今 开2.90
- 成交量 7.77万股
- 最 低 2.65
- 昨 收 2.87
- 总市值 4571.30万
- 52周最高 20.99
- 市盈率 静 --
- 换手率 0.46%
- 52周最低 2.65
- 委 比 60.71%
- 总股本 1693.07万
- 历史最高 5174400.00
- 量 比 1.45
- 振 幅 9.06%
- 历史最低 2.65
- 每 手 1
- 风险率 2.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股夜盘 | TransCode Therapeutics, Inc.暴升21.66%，最新股价4.1美元
TransCode Therapeutics, Inc.暴升21.66%，报4.1美元
08-13 12:43
TransCode Therapeutics Updates Preferred Stock Governance Terms
TransCode Therapeutics ( ($RNAZ) ) has shared an announcement. TransCode Therap...
08-04 05:02
TransCode Therapeutics Shareholders Approve Key Capital Measures
TransCode Therapeutics ( ($RNAZ) ) has shared an update. On July 20, 2026, Tran...
07-21 04:51
TransCode Therapeutics Updates Preferred Stock Ownership Limits
An announcement from TransCode Therapeutics ( ($RNAZ) ) is now available. On Ju...
07-18 05:33
TransCode Highlights Progress of Lead RNA Cancer Therapeutic
An update from TransCode Therapeutics ( ($RNAZ) ) is now available. On June 18,...
06-18 20:39
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study
TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, showing safety and disease stabilization in patients with advanced cancer.
06-03 19:41
TransCode启动TTX-MC138针对ctDNA阳性结直肠癌患者的2a期临床试验
临床阶段肿瘤公司TransCode Therapeutics， Inc．（纳斯达克代码：RNAZ）今日宣布，正式启动其领先候选药物TTX-MC138的2a期...
05-28 03:38
TransCode Therapeutics Receives Nasdaq Listing Deficiency Notice
An update from TransCode Therapeutics ( ($RNAZ) ) is now available. On May 19, ...
05-23 06:10
TransCode Therapeutics Q1 EPS $(21.28) Up From $(70.16) YoY
TransCode Therapeutics (NASDAQ:RNAZ) reported quarterly losses of $(21.28) per share. This is a 69.67 percent increase over losses of $(70.16) per share from the same period last year.
05-16 06:43
